Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

A Decade From Now, You'll Regret Not Buying This 1 Small-Cap Stock

Small-cap stocks rarely receive the limelight they deserve. A handful of small-cap companies are quietly laying the groundwork for long-term success. They are expanding market share, improving profitability, and scaling their business models while most investors ignore them for the short-term volatility.

With a market cap of $2.07 billion, Alphatec Holdings (ATEC) is one such small-cap stock that investors may regret not buying 10 years from now.

Fundamentals

See More
  • Market Capitalization, $K 598,691,136
  • Shares Outstanding, K 2,409,899
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,550 M
  • EBITDA $ 38,053 M
  • 60-Month Beta 0.35
  • Price/Sales 6.36
  • Price/Cash Flow 17.24
  • Price/Book 7.19

Options Overview Details

View History
  • Implied Volatility 23.86% (+1.99%)
  • Historical Volatility 13.26%
  • IV Percentile 97%
  • IV Rank 50.32%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 5) 5.37 (2.16%)
  • Put/Call Vol Ratio 0.86
  • Today's Volume 29,816
  • Volume Avg (30-Day) 44,451
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 376,021
  • Open Int (30-Day) 370,857
  • Expected Range 243.06 to 253.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.68
  • Number of Estimates 8
  • High Estimate 2.85
  • Low Estimate 2.41
  • Prior Year 2.77
  • Growth Rate Est. (year over year) -3.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
225.33 +10.25%
on 01/30/26
248.94 -0.20%
on 02/27/26
+23.99 (+10.69%)
since 01/27/26
3-Month
199.90 +24.27%
on 12/09/25
248.94 -0.20%
on 02/27/26
+40.87 (+19.69%)
since 11/26/25
52-Week
141.50 +75.57%
on 04/09/25
248.94 -0.20%
on 02/27/26
+84.70 (+51.73%)
since 02/27/25

Most Recent Stories

More News
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3

JNJ : 248.43 (+2.04%)
A Decade From Now, You'll Regret Not Buying This 1 Small-Cap Stock

The best long-term winners often start small.

SYK : 387.46 (+0.36%)
$SPX : 6,878.88 (-0.43%)
JNJ : 248.43 (+2.04%)
MDT : 97.66 (+0.65%)
ISRG : 503.51 (-0.66%)
ATEC : 13.62 (-2.78%)
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Data from the pivotal ENERGY trial showed IMAAVY ® produced a rapid and durable hemoglobin response a in wAIHA

JNJ : 248.43 (+2.04%)
Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

$NASX : 22,668.21 (-0.92%)
JNJ : 248.43 (+2.04%)
LLY : 1,051.99 (+2.93%)
Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

$SPX : 6,878.88 (-0.43%)
JNJ : 248.43 (+2.04%)
LLY : 1,051.99 (+2.93%)
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA ® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease...

JNJ : 248.43 (+2.04%)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™ ; results surpass current standards of care

JNJ : 248.43 (+2.04%)
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines ...

JNJ : 248.43 (+2.04%)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO ™ beyond lung cancer

JNJ : 248.43 (+2.04%)
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Monthly dosing reduces treatment visits while maintaining established safety and efficacy 1,2

JNJ : 248.43 (+2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 257.19
2nd Resistance Point 253.06
1st Resistance Point 250.75
Last Price 248.43
1st Support Level 244.31
2nd Support Level 240.18
3rd Support Level 237.87

See More

52-Week High 248.94
Last Price 248.43
Fibonacci 61.8% 207.90
Fibonacci 50% 195.22
Fibonacci 38.2% 182.54
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar